Wall Street can punish stocks quickly, but investors will return to a
solid story almost as quickly. It was only about a year ago when St. Jude Medical (NYSE: STJ )
shares were hammered on worries that lead failures would severely
compromise the company's ICD business and that the company was trailing
major rivals like Medtronic (NYSE: MDT ) and Johnson & Johnson (NYSE: JNJ ) in key growth market opportunities.
Since then, sentiment has come back around in a big way. Not only
does the company appear to be gaining some share in its cardiac rhythm
management, or CRM, business, but the atrial fibrillation business has
also been performing well. Add to that interesting opportunities in
heart failure monitoring, neurostim, ablation, renal denervation,
transcatheter heart valv
Please follow the link to read the full article:
http://www.fool.com/investing/general/2013/10/16/st-jude-firmly-back-in-wall-streets-good-graces.aspx
No comments:
Post a Comment